BSBE (300406.SZ) investee company Zhongke Natai plans to implement equity restructuring.

Zhitong Finance APP News, Jiuqiang Biology (300406.SZ) issued an announcement that the company recently received a notice from Zhongke Natai. Due to tight operating funds at Zhongke Natai, and its original A1 round investor Hangzhou Junze No. 1 Enterprise Service Partnership (Limited Partnership) (hereinafter referred to as "Junze No. 1") has initiated arbitration over equity repurchase matters (the repurchase price involved is RMB 8 million), in order to properly resolve Junze No. 1's exit, resolve the operating difficulties, and promote subsequent financing, Zhongke Natai plans to implement an equity restructuring plan. According to the plan, the company intends to subscribe for an additional RMB 26,212 of registered capital of Zhongke Natai at a price of RMB 1 per each RMB 1 of registered capital, with a total subscription price of RMB 26,212, all of which will be included in registered capital; as part of the overall arrangement for this equity restructuring, the company and other original investors agree to waive the repurchase rights and rights of first refusal under the Shareholders Agreement signed by all parties in November 2021. After the completion of this restructuring, the company will hold 6.3520% equity in Zhongke Natai. The source of funds for this transaction is the company's own funds.